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nsulin-like growth factors promote myoblast differentiation
through phosphoinositol 3-kinase and Akt signaling.
Akt substrates required for myogenic differentiation are
unknown. Forkhead transcription factors of the forkhead
box gene, group O (Foxo) subfamily are phosphorylated
 
in an insulin-responsive manner by phosphatidylinositol
 
3-kinase–dependent kinases. Phosphorylation leads to nuclear
exclusion and inactivation. We show that a constitutively
 
active Foxo1 mutant inhibits differentiation of C
 
2
 
C
 
12
 
 cells
and prevents myotube differentiation induced by constitu-
I
 
tively active Akt. In contrast, a transcriptionally inactive
mutant Foxo1 partially rescues inhibition of C
 
2
 
C
 
12
 
 differen-
tiation mediated by wortmannin, but not by rapamycin,
and is able to induce aggregation-independent myogenic
conversion of teratocarcinoma cells. Inhibition of Foxo
expression by siRNA resulted in more efﬁcient differentia-
tion, associated with increased myosin expression. These
observations indicate that Foxo proteins are key effectors of
Akt-dependent myogenesis.
 
Introduction
 
Muscle development is a multi-step process that begins with
the determination of myogenic precursors from mesodermal
stem cells and concludes with differentiation of committed
myoblasts (McKinsey et al., 2001). This program depends
 
on myogenic effectors of the MyoD family (Weintraub et al.,
 
1991) and their cooperation with myocyte-specific enhancer-
binding factors, such as MEF2 (McKinsey et al., 2001).
 
These proteins activate expression of genes required for muscle
differentiation through heterodimer formation with other
ubiquitous bHLH proteins and by binding to E boxes, cis-
acting elements found in the promoter regions of muscle-
restricted genes (Olson and Klein, 1994).
Most peptide growth factors stimulate myoblast proliferation
and prevent differentiation (Coolican et al., 1997). In contrast,
insulin-like growth factors (IGFs) promote myoblast differ-
entiation in vitro (Coolican et al., 1997; Tureckova et al.,
2001). In cultured myoblasts, autocrine production of IGF2
is associated with differentiation triggered by serum with-
drawal (Rosenthal et al., 1991; Stewart and Rotwein, 1996;
Lawlor and Rotwein, 2000a). Inactivation of IGF signaling
by targeted mutagenesis of the gene-encoding IGF1 receptor
leads to muscle hypoplasia (Liu et al., 1993), whereas IGF1
overexpression in muscle results in enlarged myofibers
(Coleman et al., 1995), suggesting that IGFs participate in
myogenesis in vivo.
IGF signaling activates the phosphatidylinositol 3-kinase
(PI 3-kinase) and the MAPK pathways (Kim and Accili,
2002). Although several reports indicate a requirement for
PI 3-kinase activity in the activation of myogenic program
(Jiang et al., 1998; Kaliman et al., 1998), the MAPK pathway
does not appear to contribute to IGF-dependent myogenesis
(Coolican et al., 1997; Lawlor et al., 2000; Tureckova et al.,
2001; Conejo et al., 2002). Among the effectors of PI 3-kinase,
the serine/threonine kinase Akt has been shown to induce
transcription of muscle-specific genes (Jiang et al., 1999),
thus resulting in myoblast differentiation (Lawlor et al.,
2000; Lawlor and Rotwein, 2000b). However, Akt sub-
strates required for completion of the myogenic process are
 
unknown. Some evidence indicates that p70
 
s6k1
 
 participates
in myogenesis (Cuenda and Cohen, 1999), whereas the role
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of mTOR is unclear. Analyses with the mTOR inhibitor ra-
pamycin have yielded conflicting results, with some suggest-
ing that rapamycin inhibits (Coolican et al., 1997; Cuenda
and Cohen, 1999; Conejo et al., 2002) and others suggest-
ing that rapamycin promotes myoblast differentiation (Er-
bay and Chen, 2001). Notably, other authors have reported
no effect of rapamycin in this process (Canicio et al., 1998).
Forkhead transcription factors of the forkhead box gene,
group O (Foxo) subfamily (Kaestner et al., 2000) are phos-
phorylated in an insulin-responsive manner by Akt and Sgk
(Brunet et al., 1999, 2001; Nakae et al., 2000). Phosphoryla-
tion leads to Foxo inhibition through nuclear exclusion. Foxo
proteins mediate several transcriptional effects of insulin and
IGFs, including those on hepatic glucose production (Nakae et
al., 2001b, 2002), pancreatic 
 
 
 
-cell proliferation (Kitamura et
al., 2002), and adipocyte differentiation (Nakae et al., 2003).
To study the role of Foxo proteins in myoblast differentiation,
we examined the effects of constitutively active and dominant-
negative mutant Foxo1 on in vitro differentiation of cultured
myoblasts, teratocarcinoma cells, and rhabdomyosarcoma cells.
To examine pathways impinging on Foxo1 regulation of myo-
genesis, we also studied the ability of Foxo1 mutants to regu-
late myoblast differentiation in the presence of pharmacologi-
cal inhibitors of the PI 3-kinase and mTOR pathways, as well
as constitutively active Akt. Our data identify Foxo proteins as
key effectors of Akt-dependent myogenesis.
 
Results and discussion
 
Expression and phosphorylation of Foxo 
isoforms during differentiation
 
C
 
2
 
C
 
12
 
 cells undergo growth arrest and induction of the myo-
genic program after incubation in serum-free medium.
There are three Foxo isoforms in mice: Foxo1, -3 and -4
(Kaestner et al., 2000). 
 
Foxo4
 
 and 
 
Foxo1
 
 are the most abun-
dant transcripts in skeletal muscle (Kitamura et al., 2002). Us-
ing Western analysis, we measured expression of the three
proteins in myoblasts and myotubes. The relative abundance
of all three isoforms declined in myotubes compared with myo-
blasts, but the difference was not statistically significant (Fig. 1
A). Next, we used phospho-specific antibodies to measure
phosphate content of the main phosphorylation site (S253 in
Foxo1, S193 in Foxo4). In myotubes, phosphate content in-
creased by 38 and 40% for Foxo1 and Foxo4, respectively. To
measure Foxo3 phosphorylation, we used an electrophoretic
gel shift assay. We detected an 85% increase in the amount of
low mobility (phosphorylated) protein in myotubes (Fig. 1
B). These data indicate that differentiation is associated with
increased Foxo phosphorylation. From these observations, it
can be inferred that myogenic differentiation requires Foxo1
inhibition, similar to what has been observed in adipocytes
(Nakae et al., 2003) and thymocytes (Leenders et al., 2000).
 
Foxo1 mutants modulate myoblast differentiation
 
Because Akt mediates IGF-dependent C
 
2
 
C
 
12
 
 differentiation
(Lawlor and Rotwein, 2000b; Tureckova et al., 2001) and
Foxo isoforms are Akt substrates (Brunet et al., 1999), we
investigated whether they mediate myoblast differentiation.
We used adenovirus-mediated gene transfer to express con-
 
stitutively active (ADA) and dominant-negative (
 
 
 
256)
Foxo1 mutants in myoblasts. The constitutively active mu-
tant cannot be phosphorylated and fails to translocate in re-
sponse to insulin, whereas the dominant-negative mutant
lacks the transactivation domain (Nakae et al., 2000). The
 
 
 
256-Foxo1 or ADA-Foxo1 adenoviruses were expressed at
high levels after transduction (Fig. 2 A, lane 2 and lane 3).
After 96 h in differentiation medium, cells transduced with
Figure 1. Foxo isoform expression and phosphorylation levels in 
C2C12 myoblasts and myotubes. (A) Extracts of C2C12 myoblasts and 
myotubes were immunoblotted with the antisera indicated on the 
right side. (B) Levels of phosphorylated Foxo1 and Foxo4 were 
assessed by immunoblotting with phospho-specific antisera (S253 
for Foxo1, S193 for Foxo4), whereas electrophoretic gel mobility 
shift was used as a surrogate measure of Foxo3 phosphorylation. 
The phosphorylated protein migrates more slowly on SDS-PAGE. 
Mean   SEM of densitometric scanning values was calculated from 
three independent experiments. Immunoblotting with anti-cyclophilin 
antiserum was used as a control for gel loading (not depicted). 
Asterisk indicates P   0.01.T
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the ADA mutant failed to convert to myotubes, whereas
cells transduced with the 
 
 
 
256 mutant were morphologi-
cally indistinguishable from control cells (Fig. 2 B). Accord-
ingly, the ADA mutant prevented expression of myosin
heavy chain (MyHC), a marker of terminally differentiated
myotubes. Conversely, transduction with 
 
 
 
256 caused a
30% increase in MyHC expression (Fig. 2, B and C).
Myogenin is an early differentiation marker. In myoblasts,
its expression was induced between 4 and 8 h of serum with-
drawal. The transient decrease in myogenin expression dur-
ing differentiation has been observed by others (Langley et
al., 2002), and does not appear to interfere with the cells’
ability to undergo complete differentiation into myotubes
(Fig. 2 B). Cells transduced with 
 
 
 
256 showed a 70% in-
crease of myogenin levels compared with untransduced cells.
In contrast, ADA-transduced cells showed a 20% decrease
(Fig. 2 D). These data are consistent with the observation
that the Foxo1 gain-of-function mutant impairs differentia-
tion, whereas the dominant-negative Foxo1 increases the ef-
ficiency of differentiation.
The effect of the ADA mutant could not be accounted for
by nonspecific inhibition of Akt function because phosphor-
ylation of Gsk3, another Akt substrate, was unaffected in
cells expressing the ADA-Foxo1 mutant (Fig. 2 E).
Figure 2. Expression of early and late differentiation markers in C2C12 
transduced with Foxo1 mutants. (A) Expression of Foxo1 mutants following 
adenovirus-mediated gene transfer. Extracts from control cells (lane 1) or 
from cells transduced with D256-Foxo1 (lane 2) or ADA-Foxo1 (lane 3) 
were analyzed by immunoblotting with anti-Foxo1 antiserum. (B) Detection 
of myosin expression by immunocytochemistry. (C) Immunoblot analysis 
of MyHC expression in cells expressing ADA-Foxo1 or  256-Foxo1. A 
representative blot is shown at the top, and a graph summarizing several 
experiments is shown on the bottom. The same filter was stripped and 
reprobed with anti-cyclophilin antiserum (Cy) to normalize protein content (bottom). Asterisk indicates P   0.01. (D) Myogenin expression 
in cells expressing mutant Foxo1. Extracts were obtained from untransduced cells (lanes 1–3), cells expressing  256-Foxo1 (lanes 4–6), 
and ADA-Foxo1 (lanes 7–9) at the indicated time points and analyzed by SDS-PAGE, followed by immunoblot with anti-myogenin (top) 
or anti-cyclophilin antiserum (bottom). Data from three separate experiments are summarized in the bar graphs at the bottom. Scanning 
densitometry of the autoradiograms was used to measure MyHC and myogenin expression. Data are plotted as mean   SEM. An asterisk 
indicates P   0.01. (E) Phosphorylation of Gsk3 in cells transduced with ADA-Foxo1. Lysates were analyzed by Western blotting with a 
phosphoSer
9–21-specific Gsk3 antiserum (top) and a total Gsk3 antiserum (bottom).T
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We obtained additional evidence that Foxo inhibition is
required for differentiation using siRNA to decrease Foxo
mRNA levels. We designed two siRNAs, one directed
against a Foxo1-specific sequence, and one against a pan-
Foxo–specific sequence. Transfection of the pan-Foxo siRNA
resulted in 70–90% decreases in mRNA levels encoding all
three isoforms (Fig. 3 A), and was accompanied by a 30%
increase in MyHC expression (Fig. 3 C). In contrast, trans-
fection of the Foxo1-specific siRNA inhibited expression of
Foxo1 (Fig. 3 B), but not of Foxo3 and -4, and induced a
lesser increase in MyHC expression (Fig. 3 C).
 
 
 
256 Foxo1 partly rescues wortmannin inhibition of 
myoblast differentiation
 
Inhibition of PI 3-kinase prevents myoblast differentiation
(Jiang et al., 1998; Tureckova et al., 2001). Because Foxo
proteins are regulated by PI 3 kinase–dependent and –inde-
pendent pathways (Brunet et al., 2001; Nakae et al., 2001a),
we evaluated the ability of 
 
 
 
256 to rescue inhibition of
myogenesis by wortmannin. Treatment with wortmannin
inhibited differentiation and prevented MyHC expression.
Transduction with 
 
 
 
256 restored MyHC expression to
 
 
 
50% of control levels and was associated with partial res-
toration of the myotube phenotype (Fig. 4 A). These data
indicate that Foxo1 mediates some of the effects of PI 3-kinase
on differentiation. However, the failure of 
 
 
 
256 to com-
pletely reverse the effect of wortmannin is consistent with
the presence of Foxo-independent mechanisms of myogene-
sis downstream of PI 3-kinase.
 
ADA Foxo1 prevents differentiation 
induced by Myr-Akt
 
Akt stimulates myoblast differentiation (Coolican et al.,
1997; Lawlor and Rotwein, 2000b). Transduction with a
constitutively active Myr-Akt promoted differentiation and
increased MyHC expression twofold. However, cotransduc-
tion of Myr-Akt and ADA-Foxo1 prevented differentiation
induced by Myr-Akt and decreased MyHC expression to the
same levels seen in cells transduced with ADA-Foxo1 alone
(Fig. 4 B). These data suggest that Akt-induced myogenesis
is mediated by Foxo.
 
 
 
256-Foxo1 fails to reverse rapamycin 
inhibition of differentiation
 
Among the PI 3-kinase effectors, some authors have shown
that p70
 
s6k
 
 is required for differentiation (Coolican et al.,
1997; Cuenda and Cohen, 1999; Conejo et al., 2002). Inhi-
bition of mTOR by rapamycin resulted in an approximate
70% decrease of MyHC levels and blocked myogenic differ-
entiation. The inhibition of MyHC expression by rapamy-
cin was unaffected by 
 
 
 
256-Foxo1 (Fig. 4 C; P 
 
  
 
0.001),
suggesting that the mTOR pathway does not act through
Foxo to promote differentiation.
 
 
 
256-Foxo1 induces differentiation of teratocarcinoma, 
but not of rhabdomyosarcoma cells
 
P19 teratocarcinoma cells are able to undergo myogenic
conversion when cultured with DMSO. When P19 cells
were transduced with the 
 
 
 
256-Foxo1, differentiation oc-
Figure 3. siRNA-mediated inhibition of 
Foxo expression. Expression of mRNA 
encoding the three Foxo isoforms in cells 
transfected with increasing concentrations 
of pan-Foxo (A) or Foxo1-specific siRNA 
(B). Results are expressed as a percentage 
of control. (C) Immunoblot analysis of 
MyHC expression in cells transfected 
with pan-Foxo (light gray), Foxo1-specific 
siRNA (dark gray), or control siRNA 
(black, top). The same filter was stripped 
and reprobed with anti-cyclophilin 
antiserum (Cy) to normalize protein 
content (bottom).T
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curred in the absence of DMSO, and MyHC expression in-
creased to levels similar to DMSO-treated cells (Fig. 4 D,
lanes 1–4 and bar graph). In contrast, transduction with the
ADA mutant inhibited DMSO-induced differentiation and
reduced MyHC expression by 
 
 
 
70%. Thus, a loss-of-func-
tion Foxo1 mutation enhances myoblast differentiation of
P19 cells, whereas a gain-of-function mutation impairs it.
Rhabdomyosarcoma-derived (RD) cells lack functional
IGF signaling (Merlino and Helman, 1999). Most rhab-
domyosarcomas carry chromosomal translocations in which
the DNA-binding domain of Foxo1 is fused to the trans-
activation domain of Pax3 or Pax8 (Wang et al., 1998; Mer-
lino and Helman, 1999). We tested whether Foxo1 inhibi-
tion would restore differentiation by transducing cells with
 
 
 
256-Foxo1 and by culturing them in differentiation me-
dium. However, we failed to detect morphological changes
or increases in MyHC expression (Fig. 3 D, lane 5 and lane
6). Thus, Foxo1 inhibition alone cannot rescue the trans-
formed phenotype of RD cells.
 
Conclusions
 
Our data provide evidence for a key role of Foxo transcrip-
tion factors as mediators of IGF-dependent myoblast differ-
entiation. We provide two lines of evidence to support our
conclusions. Foxo1 gain-of-function is associated with im-
paired myoblast differentiation, whereas loss-of-function is
able to partly restore inhibition of differentiation by wort-
mannin. Furthermore, constitutively active Foxo1 inhibited,
whereas dominant-negative mutant Foxo1 caused a slight,
but significant increase in the expression of differentiation
markers. Consistent with the notion that Foxo is regulated
by Akt, we also found that the ability of constitutively active
Akt to induce differentiation (Rommel et al., 2001) can be
blocked by the phosphorylation-defective Foxo1 mutant.
These data identify Foxo1 as a key component of the Akt
pathway in differentiation. This pathway requires activation
of the cell cycle inhibitor p21 (Lawlor and Rotwein, 2000b),
a Foxo1 target in differentiating adipocytes (Nakae et al.,
2003). Although we have not examined p21 expression in
C
 
2
 
C
 
12
 
, it is likely to be an important Foxo target in myo-
blasts as well.
The inability of the dominant-negative Foxo1 to com-
pletely reverse the inhibition of differentiation caused by
wortmannin suggests that multiple effectors of differentia-
tion act downstream of PI 3-kinase. Similarly, the domi-
nant-negative Foxo1 failed to reverse rapamycin inhibition
of myoblast differentiation, indicating that Foxo1 phosphor-
ylation by mTOR is not required for this process. We sug-
gest that signals regulating myoblast differentiation diverge
downstream of PI 3-kinase, with both Akt and mTOR play-
ing a role in the process.
Foxo1 inhibition restored myogenic differentiation of te-
ratocarcinoma-derived cells, but not of rhabdomyosarcoma-
derived cells. RD cells express myogenic factors, such as
Figure 4. Signaling pathways involved in Foxo1 
regulation of myoblast differentiation. (A)  256-Foxo1 
partly rescues wortmannin inhibition of myoblast 
differentiation. C, control cells; W, wortmannin-treated 
cells;  , cells expressing  256-Foxo1;     W,   256-
expressing cells that have been treated with wortmannin. 
Extracts were obtained 96 h after the induction of 
differentiation. The bar graph summarizes the results 
of three experiments. (B) ADA-Foxo1 overrides the 
effect of Myr-Akt to stimulate myoblast differentiation. 
Extracts from control cells (C) and cells transduced 
with Myr-Akt (Myr), ADA-Foxo1 (ADA), or both (Myr   
ADA) were prepared 96 h after the induction of 
differentiation. Equal amounts of protein were subjected 
to SDS-PAGE and were immunoblotted with anti-MyHC 
(top) or anti-cyclophilin antiserum (bottom). (C)  256-
Foxo1 fails to override the inhibitory effect of rapamycin 
on C2C12 differentiation. Immunoblot analyses with 
anti-MyHC (top) and anti-cyclophilin (bottom) antisera 
were performed on extracts obtained from control (C), 
rapamycin-treated (R), and  256-expressing cells 
(    R) as indicated above. (D)  256-Foxo1 induces 
myogenic conversion of P19 teratocarcinoma cells 
independently of DMSO treatment. P19 cells were 
differentiated in the presence (lane 1 and lane 4) 
or absence (lane 2 and lane 3) of DMSO and were 
transduced with either  256-Foxo1 (lane 2) or ADA-
Foxo1 (lane 4). Lane 5 and lane 6 show control RD 
cells and RD transduced with  256-Foxo1. The bar 
graphs represent mean   SEM densitometric values 
from three or four experiments for each condition. 
One asterisk indicates P   0.01 in A–C, and P   0.005 
in D. Cyclophilin was used to normalize gel loading.T
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MyoD and myogenin, but these factors are transcriptionally
inactive (Tapscott et al., 1993). It has also been shown that
RDs are defective in their PI 3-kinase
 
→
 
Akt signaling (Xu et
al., 2002), and that constitutively active forms of PI 3-kinase
and Akt fail to restore differentiation. Now, we extend those
data by showing that inhibition of Foxo1 function is equally
unable to restore the differentiated phenotype, suggesting
that the defect in RD cells is distal to Foxo1.
After the submission of this manuscript, it has been re-
ported that Foxo1 promotes differentiation of primary myo-
blasts (Bois and Grosveld, 2003). These conclusions are at
odds with our data, and appear to be due to substantial dif-
ferences in the experimental system, such as the dissociation
of Foxo1 phosphorylation from nuclear localization, the lack
of Akt regulation of Foxo1, and the failure of dominant-neg-
ative Akt to affect differentiation.
In conclusion, we show that Foxo1 plays in important role
in regulating skeletal muscle differentiation through the
PI3K
 
→
 
Akt pathway. Further work will identify Foxo1 tar-
gets involved in this process.
 
Materials and methods
 
Reagents
 
We obtained C
 
2
 
C
 
12
 
, P19, and RD cells from the American Type Culture
Collection, anti- Foxo1 antibodies from Santa Cruz Biotechnology, Inc.,
anti-HA antibody 12CA5 from Boehringer, anti-MyHC (clone MF 20) and
anti-myogenin antibodies (clone F5D) from the Hybridoma Bank (Univer-
sity of Iowa, Iowa City, IA), and anti phospho-Gsk3 and anti-Gsk3 antisera
from Upstate Biotechnology. C
 
2
 
C
 
12
 
, P19 (Wilton and Skerjanc, 1999), and
RD cells (Merlino and Helman, 1999) were maintained and differentiated
as described previously (Astolfi et al., 2001). Foxo1 and Akt adenoviral
vectors have been described previously (Nakae et al., 2001b). Western
blotting was performed according to standard procedures.
 
Design and transfection of siRNAs
 
We used the target finder and design tool (Ambion) to identify target
siRNAs. The Foxo1-specific sequence was 5
 
 
 
-AAAAGTCCTTCAGATTG-
TCTG-3
 
 
 
. The pan-Foxo sequence was 5
 
 
 
-AAGGATAAGGGCGACA-
GACC-3
 
 
 
. SiRNA synthesis and transfection with siPORT™ reagents was
performed according to the manufacturer’s instructions (Ambion). Foxo ex-
pression was measured by real-time RT-PCR using a LightCycler PCR in-
strument (Roche) and LightCycler SYBR
 
®
 
 Green I reaction mix (Roche).
Each reaction was performed in triplicate under standard reaction condi-
tions. 
 
 
 
-Actin was used as a control of amplification efficiency.
 
Immunofluorescence
 
Cells were cultured on microscope slides, differentiated, and fixed in 4%
PFA. After incubation with anti-MyHC IgG2b at 1:500, detection was per-
formed using DAPC-conjugated secondary antibody (Nakae et al., 2003).
 
Statistical analysis
 
Statistical analysis was performed using 
 
t
 
 test for paired data.
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